News & Updates
Filter by Specialty:
Meta-analysis: No link between PPI use and gastric cancer
Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.
Meta-analysis: No link between PPI use and gastric cancer
11 Jan 2023
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
08 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023
Repeat transurethral resection of bladder tumour predicts but does not improve survival
Repeat transurethral resection of bladder tumour prior to radical cystectomy, regardless of whether or not neoadjuvant chemotherapy is administered, does not seem to improve survival in patients with muscle-invasive bladder cancer, reveals a recent study.
Repeat transurethral resection of bladder tumour predicts but does not improve survival
07 Jan 2023
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.